Protagenic Therapeutics Files 8-K
Ticker: PTIXW · Form: 8-K · Filed: May 5, 2025 · CIK: 1022899
| Field | Detail |
|---|---|
| Company | Protagenic Therapeutics, Inc.\New (PTIXW) |
| Form Type | 8-K |
| Filed Date | May 5, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-update, financials, filing
Related Tickers: PTIX
TL;DR
PTIX filed an 8-K on 5/2/25 for corporate updates and financials.
AI Summary
Protagenic Therapeutics, Inc. filed an 8-K on May 2, 2025, reporting amendments to its articles of incorporation or bylaws and financial statements. The company, formerly known as Atrinsic, Inc., is incorporated in Delaware and has its fiscal year end on December 31.
Why It Matters
This filing indicates corporate updates and the submission of financial statements, which are crucial for investors to understand the company's current status and financial health.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not contain information that inherently increases risk.
Key Numbers
- 1231 — Fiscal Year End (Indicates the end of the company's financial reporting year.)
Key Players & Entities
- Protagenic Therapeutics, Inc. (company) — Filer
- Atrinsic, Inc. (company) — Former company name
- May 2, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-12555 (identifier) — SEC file number
FAQ
What specific amendments were made to Protagenic Therapeutics' articles of incorporation or bylaws?
The filing indicates that amendments were made, but the specific details of these amendments are not provided in the summary information.
What is the significance of filing financial statements with this 8-K?
Filing financial statements provides investors with updated financial information about the company's performance and position.
When was Protagenic Therapeutics, Inc. previously known as Atrinsic, Inc.?
The date of the name change from Atrinsic, Inc. to Protagenic Therapeutics, Inc. is not explicitly stated in the provided text, only that Atrinsic, Inc. was a former name.
What is the company's primary industry classification?
Protagenic Therapeutics, Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]'.
What is the SEC file number for this report?
The SEC file number for this 8-K filing is 001-12555.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 5, 2025 regarding Protagenic Therapeutics, Inc.\new (PTIXW).